These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 25888291)

  • 1. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
    Bencsikova B; Bortlicek Z; Halamkova J; Ostrizkova L; Kiss I; Melichar B; Pavlik T; Dusek L; Valik D; Vyzula R; Zdrazilova-Dubska L
    BMC Gastroenterol; 2015 Mar; 15():37. PubMed ID: 25888291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
    Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
    Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
    Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
    N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
    Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
    Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.